-

Aptar Declares Quarterly Dividend

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is August 14, 2025 to stockholders of record as of July 24, 2025.

As previously announced, Aptar will hold a conference call on Friday, August 1, 2025 at 8:00 a.m. Central Time to discuss the Company’s second quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website.

About Aptar

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Contacts

Investor Relations Contact:
Mary Skafidas
Mary.skafidas@aptar.com
+1 347-351-6407

Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815-479-5671

AptarGroup, Inc.

NYSE:ATR

Release Summary
Aptar Declares Quarterly Dividend
Release Versions

Contacts

Investor Relations Contact:
Mary Skafidas
Mary.skafidas@aptar.com
+1 347-351-6407

Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815-479-5671

More News From AptarGroup, Inc.

Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate...

Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™...

Aptar Announces 2026 Quarterly Conference Call Dates

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces 2026 Quarterly Conference Call Dates...
Back to Newsroom